Nukepills.com today announced the sale of 180,000 units (5.4 million doses) of ThyroShield(TM) Potassium Iodide to the Kuwait Ministry of Health. Worth approximately $1.4 million, the sale was brokered by Nukepills.com and signifies Kuwait’s proactive course in protecting its citizens during a nuclear radiation emergency. “This sale is the first large-scale order of ThyroShield from a foreign government. We are currently working on additional potassium iodide orders from other countries in the Middle East, Europe and Asia. We hope the new U.S. administration follows Kuwait’s lead and reinstitutes the potassium iodide distribution plan to protect its citizens,” said Troy Jones, President of Nukepills.com. ThyroShield(TM) Potassium Iodide Oral Solution is a ready-to-use, thyroid-blocking liquid medicine for radiation emergencies. Stockpiling of potassium iodide is recommended by health officials worldwide to prevent thyroid cancer in those exposed to radioactive iodine in the event of a nuclear reactor accident or fallout from a nuclear weapon. Potassium iodide protects against the harmful effects of radioactive iodine by preventing its absorption by the thyroid gland. Thyroid cells are the only cells in the human body that can absorb iodine, and are thus the only cells at risk for cancer. ThyroShield(TM) is manufactured by Fleming Pharmaceuticals of Fenton, Missouri.